Biotech entity
All 2 tracked stories fall under one category: pharma. UroGen Pharma is most often covered alongside Accu-Fab, which appears in 1 of these 2 stories. Source depth averages 7 original sources per story, versus 3.7 across the same-window beat baseline.
Last mentioned: Aug 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. UroGen Pharma is most often covered alongside Accu-Fab, which appears in 1 of these 2 stories. Source depth averages 7 original sources per story, versus 3.7 across the same-window beat baseline. The 159-day window averages about 0.1 stories each week. At 5.5, the average consequence score sits below the same-window beat average of 6.2. We currently track 2 Biotech stories that mention UroGen Pharma, published between March 3, 2026 and August 8, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 565 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UroGen Pharma. Shared-story counts are live from our verified record — not editorial picks.
Urogen Pharma’s bladder cancer therapy ZUSDURI generated $50.4M in Q2 net product revenue, a 73% sequential jump, as the company activated 1,444 accounts and doubled repeat prescribers. The strong commercial launch highlights robust demand in biotech’s niche oncology space.
Source: themarketsdaily.com · dailypolitical.com
UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
UroGen Pharma is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
